FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: Expression of central nervous system genes and reversal of blood-brain-barrier damage

Brain Pathology

Volumn 19, Issue 2, 2009, Pages 254-266

  Foster, Carolyn A ^a   Mechtcheriakova, Diana ^a,b   Storch, Maria K ^f   Balatoni, Balázs ^a,c   Howard, Laurence M ^a   Bornancin, Frédéric ^a   Wlachos, Alexander ^a   Sobanov, Jury ^a,d   Kinnunen, Anu ^e,g   Baumruker, Thomas ^a  

^a Novartis Institutes for BioMedical Research Vienna   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Novartis Hungary Healthcare   (Hungary)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Kontiolahti Health Center   (Finland)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

EAE; Experimental autoimmune encephalomyelitis; Fingolimod; FTY720; Gene expression; Multiple sclerosis; Sphingosine 1 phosphate

Indexed keywords

CD14 ANTIGEN; CD1D ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHITINASE 3 LIKE PROTEIN 1; COMPLEMENT COMPONENT C1R; CYTOSOLIC PHOSPHOLIPASE A2; FINGOLIMOD; GAMMA INTERFERON; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; LYASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; SPHINGOSINE 1 PHOSPHATE LYASE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; SPHINGOSINE 1 PHOSPHATE RECEPTOR 4; SPHINGOSINE 1 PHOSPHATE RECEPTOR 5; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DARK AGOUTI RAT; DEMYELINATION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION PROFILING; GLIA CELL; LYMPHOCYTIC INFILTRATION; NEUROMODULATION; NONHUMAN; PROTEIN DEGRADATION; RAT; TREATMENT RESPONSE;

ANIMALS; ANTIGENS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN; CAPILLARY PERMEABILITY; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION REGULATION; IMMUNIZATION; IMMUNOSUPPRESSIVE AGENTS; MYELIN PROTEINS; PHOSPHOLIPASES A2, CYTOSOLIC; POLYMERASE CHAIN REACTION; PROPYLENE GLYCOLS; RANDOM ALLOCATION; RATS; SPHINGOSINE; SPINAL CORD;

EID: 61649121740     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2008.00182.x     Document Type: Article

References (49)

1. Alt C, Duvefelt K, Franzén B, Yang Y, Engelhardt B (2005) Gene and protein expression profiling of the microvascular compartment in experimental autoimmune encephalomyelitis in C57Bl/6 and SJL mice. Brain Pathol 15 : 1 16.
2. Arnett HA, Wang Y, Matsushima GK, Suzuki K, Ting JP-Y (2003) Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 23 : 9824 9832.
3. Balatoni B, Storch MK, Swoboda EM, Schönborn V, Koziel A, Lambrou GN et al (2007) FTY720 sustains and restores neuronal function in MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74 : 307 316.
4. Bandhuvula P, Tam YY, Oskouian B, Saba JD (2005) The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol Chem 280 : 33697 33700.
5. Barral DC, Brenner MB (2007) CD1 antigen presentation: how it works. Nat Rev Immunol 7 : 929 941.
6. Baumruker T, Billich A, Brinkmann V (2007) FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs 16 : 283 289.
7. Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V (2006) Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg 108 : 124 128.
8. Bräuer AU, Savaskan NE, Kühn H, Prehn S, Ninnemann O, Nitsch R (2003) A new phospholipid phosphatase, PRG-1, is involved in axon growth and regenerative sprouting. Nat Neurosci 6 : 572 578.
9. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R et al (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277 : 21453 21457.
10. Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38 : 788 796.
11. Bußhoff U, Hein A, Iglesias A, Dörries R, Régnier- Vigouroux A (2001) CD1 expression is differentially regulated by microglia, macrophages and T cells in the central nervous system upon inflammation and demyelination. J Neuroimmunol 113 : 220 230.
12. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C (2007) The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 323 : 626 635.
13. Comabella M, Martin R (2007) Genomics in multiple sclerosis - current state and future directions. J Neuroimmunol 187 : 1 8.
14. Cunningham LA, Wetzel M, Rosenberg GA (2005) Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50 : 329 339.
15. Cunningham TJ, Yao L, Oetinger M, Cort L, Blankenhorn EP, Greenstein JI (2006) Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroinflammation 3 : 26 33.
16. + regulatory T cells. J Immunol 178 : 2458 2468.
17. Felderhoff-Mueser U, Schmidt OI, Oberholzer A, Bührer C, Stahel PF (2005) IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci 28 : 487 493.
18. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B et al (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323 : 1 8.
19. Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, Li X-K (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305 : 70 77.
20. Hafler DA, Compston A, Sawcer S, The International Multiple Sclerosis Genetics Consortium (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357 : 851 862.
21. Herr DR, Chun J (2007) Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 8 : 155 167.
22. Hiestand PC, Rausch M, Piani Meier D, Foster CA (2008) Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720. In : Natural Products as Drugs. Prog Drug Res. F Petersen, R Amstutz (eds 66 : 362 381. Springer-Birkhäuser Verlag : Basel, Switzerland.
23. Jorgensen SH, Storm N, Jensen PE, Laursen H, Sorensen PS (2007) IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Exp Brain Res 178 : 462 469.
24. Jung CG, Kim HJ, Miron VE, Cook S, Kennedy TE, Foster CA et al (2007) Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55 : 1656 1667.
25. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH et al (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355 : 1124 1140.
26. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, Chiba K (2005) FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2 : 439 448.
27. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H et al (2007) Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 17 : 38 44.
28. Lorentzen JC, Issazadeh S, Storch M, Mustafa MI, Lassmann H, Linington C et al (1995) Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 63 : 193 205.
29. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (1999) A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 122 : 2279 2295.
30. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J et al (2002) Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science 296 : 346 349.
31. Mechtcheriakova D, Wlachos A, Sobanov J, Kopp T, Reuschel R, Bornancin F et al (2007) Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal 19 : 748 760.
32. Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek J, Jaworski J et al (2007) β-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J Biol Chem 282 : 16036 16041.
33. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP (2008) FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 63 : 61 71.
34. H1 cells control themselves by producing interleukin-10. Nat Rev Immunol 7 : 425 428.
35. Pender MP (1989) Recovery from acute experimental allergic encephalomyelitis in the Lewis rat. Early restoration of nerve conduction and repair by Schwann cells and oligodendrocytes. Brain 112 : 393 416.
36. Rubtsov YP, Rudensky AY (2007) TGFβ signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 7 : 443 453.
37. Sawcer S, Ban M, Maranian M, Yeo TW, Compston A, Kirby A et al (2005) A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 77 : 454 467.
38. Seifert T, Bauer J, Weissert R, Fazekas F, Storch MK (2005) Differential expression of sonic hedgehog immunoreactivity during lesion evolution in autoimmune encephalomyelitis. J Neuropathol Exp Neurol 64 : 404 411.
39. Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G (1999) Self glycolipids as T-cell autoantigens. Eur J Immunol 29 : 1667 1675.
40. Sia G-M, Béïque J-C, Rumbaugh G, Cho R, Worley PF, Huganir RL (2007) Interaction of the N-terminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. Neuron 55 : 87 102.
41. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M et al (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8 : 681 694.
42. Terai K, Soga T, Takahashi M, Kamohara M, Ohno K, Yatsugi S et al (2003) Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS. Neuroscience 116 : 1053 1062.
43. Tucker KL, Meyer M, Barde Y-A (2001) Neurotrophins are required for nerve growth during development. Nat Neurosci 4 : 29 37.
44. Van Veldhoven PP (2000) Sphingosine-1-phosphate lyase. Methods Enzymol 311 : 244 254.
45. Webb M, Tham C-S, Lin F-F, Lariosa-Willingham K, Yu N, Hale J et al (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153 : 108 121.
46. Weissert R, Wallström E, Storch MK, Stefferl A, Lorentzen J, Lassmann H et al (1998) MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 102 : 1265 1273.
47. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease - a double-edged sword. Neuron 35 : 419 432.
48. Yoo JK, Kwon H, Khil L-Y, Zhang L, Jun H-S, Yoon J-W (2005) IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. J Immunol 175 : 8280 8286.
49. Yu N, Lariosa-Willingham KD, Lin F-F, Webb M, Rao TS (2004) Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 45 : 17 27.